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Summary 
It is widely accepted that T  cells play an important role in the destruction of [3 cells leading to 
autoimmune type I diabetes, but the involved effector mechanisms have remained unclear. We 
addressed this issue by testing the role of perforin-dependent cytotoxicity in a disease  model in- 
volving  transgenic  mice  expressing  glycoprotein  of  lymphocytic  choriomeningitis  virus 
(LCMV-GP) in the 13 cells of the endocrine pancreas. In such mice, LCMV infection leads to a 
potent LCMV-GP-specific T  cell response resulting in rapid development of diabetes. We re- 
port here that in perforin-deficient LCMV-GP transgenic mice, LCMV infection failed to in- 
duce diabetes despite the activation ofLCMV-GP-specific T  cells. Deletion ofv~6 + T  cells in 
Mls-1 a perforin-deficient mice and the activation of LCMV-GP-specific T  cells  in perforin- 
deficient LCMV-GP transgenic mice, however, indicated that thymic tolerance induction by 
negative selection was not affected by the disruption of the perforin gene and that there is no 
fundamental difference between the T  cell repertoires of normal control and perforin-deficient 
mice. In addition, adoptive transfer of LCMV-GP-specific TCR transgenic perforin-deficient 
T  cells activated by LCMV-GP recombinant vaccinia virus led to marked insulitis with infiltra- 
tion of CD4 + and CD8 + T  cells without the development of diabetes. These findings indicate 
that perforin-dependent cytotoxicity is not required for the initiation of insuhtis but is crucial 
for the destruction of [3 cells in the later phase of the disease process. Other mechanisms or sol- 
uble factors present in the inflammatory islet infiltrate apparently lack the ability to efficiently 
induce diabetogenic 13 cell damage. 
I 
nsulin-dependent  diabetes  mellitus  is  a  progressive  au- 
.toimmune disease resulting in destruction of more than 
90%  of insuhn-producing  [3  cells  in  the  pancreatic  islets. 
The  extensive study of spontaneous  diabetes in  the  non- 
obese  diabetic  (NOD) 1 mouse  has  greatly promoted  the 
understanding  of the  pathogenic  mechanisms involved in 
the  induction  and progression  of the  disease.  It is widely 
accepted now that T  cells are crucially involved in the de- 
velopment  of diabetes in  NOD  mice.  This  conclusion  is 
based on the observation that a majority of islet-infiltrating 
cells  are  T  cells  (1),  that  diabetes  can  be  transferred  to 
young irradiated NOD mice with T  cells from diabetic an- 
imals (2, 3), and that T  cell depletion by specific antibodies 
is  able to prevent diabetes  (4).  But the  role of the  CD4  + 
helper and CD8 +  cytotoxic T  cell subset in inducing and 
perpetuating the disease is controversial. Transfer of T  cell 
1Abbreviations used in this paper: LCMV, lymphocytic  choriomeningitis vi- 
rus; LCMV-GP, glycoprotein  ofLCMV; vacc-LCMV-GP,  vaccinia  virus 
recombinant for LCMV-GP; NOD, non-obese diabetic. 
subpopulations from diabetic animals to young NOD mice 
has  shown  that both populations  are required  for the  in- 
duction of diabetes (5-7). On the other hand, injection of a 
CD4 +  T  cell  clone  or  of activated TCR  transgenic  T~ 
cells  accelerated diabetes in young NOD  mice  (8,  9).  To 
accommodate these somewhat conflicting data two discrete 
diabetogenic effector mechanisms were proposed. The first 
mechanism is mediated by MHC class I-restricted CD8 + T 
cells  inducing destruction of [3 cells by contact-dependent 
cytotoxicity.  The  second  is  mediated  by MHC  class  II- 
restricted  CD4 +  T  cells  that  recruit  nonspecific  effector 
cells  into  the  islets  by releasing  chemotactic  factors.  The 
observation that cloned CD4 + T  cells were able to induce 
diabetes in the absence of CD8 + T  cells  indicated that al- 
though CD8 + T  cells under normal conditions may be the 
more efficient effector cells  of 13 cell destruction,  CD4 + T 
cells  are  able  to  mediate  the  disease,  given  enough  time, 
numbers, and high specificity. 
Additionally, several findings supported a role for CD8 + 
T  cells  in  the  early induction  phase  of diabetes  in  NOD 
mice. First,  CD8 + T  cells appear early in the islets ofpredi- 
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later in disease progression (10). Second, 132-microglobulin- 
deficient  NOD  mice  with  an  almost  complete  lack  of 
CD8 §  T  cells do not only fail to develop diabetes but also 
lack lymphocytic infiltration into the islets (11-13).  These 
results suggested a model in which early infiltrating CD8 + 
T  cells cause a low level of islet cell lysis. The resulting re- 
lease  of 13  cell  proteins  could  prime  and/or  augment  a 
CD4 + T  cell response, which in turn is maintaining an in- 
flammatory process involving the recruitment of other ef- 
fector cells with toxicity for [3 cells. 
So  far,  these  experiments  were  not  able  to  distinguish 
between effects ofT cells mediated by cytokines, on the one 
hand, and contact-dependent cytotoxicity, on the other hand. 
Any  effector  mechanism  has  to  account  for  the  extreme 
specificity of the disease process that leads to elimination of 
islet  [3  cells but  spares  ix  cells  and  other  minor  islet  cell 
types. A  recent hypothesis proposes that IL-1 produced by 
cells in the inflammatory islet foci may account for specific 
b  cell damage by selectively inducing the formation of ni- 
tric oxide in [3 but not in ix cells (14,  15). 
To  investigate  the  role  of  T  cell-mediated  contact- 
dependent  cytotoxicity in  autoimmune  diabetes,  we  used 
pefforin-deficient mice. Perforin, which is expressed in cy- 
toplasmic  granules  of CTL  and  NK  cells, is  crucially in- 
volved in T  and NK cell-mediated cytotoxicity and in ef- 
fector functions  of T  cells and  NK  cells in vivo  (16-21). 
Since perforin-deficient mice have no  defect in ontogeny, 
activation, and proliferation ofT  cells (16), they offer a di- 
rect approach to address the role of effector mechanisms in 
the destruction of 13 cells in diabetes. 
Perforin-deficient mice were bred with transgenic mice 
expressing the  glycoprotein of lymphocytic choriomenin- 
gitis virus (LCMV-GP)  (22,  23)  in [3 cells of the pancreas. 
Normally, these mice are unresponsive but not tolerant to 
LCMV-GP. However, upon activation of LCMV-GP spe- 
cific T  cells by infection with LCMV they develop insulitis 
and diabetes in 9  to 11  d, which is dependent on CD8 §  T 
cells. This study documents that in this model system ofau- 
toimmune  diabetes the  disease process is dependent  upon 
perforin-dependent cytotoxicity. 
Materials and Methods 
Mice.  Perforin-deficient (16),  LCMV-GP-specific T  cell re- 
ceptor transgenic and normal control C57BL/6  mice were bred 
under specific pathogen-free conditions at the Institut ftir Labor- 
tierkunde (University of Ziirich, Switzerland). Since embryonic 
stem cells of C57BL/6  origin were used to generate these mice, 
they represent a mutant of the C57BL/6 strain. TCR transgenic 
mice were backcrossed in C57BL/6 background. All experiments 
were carried out with age (8-16 wk) and sex-matched animals. 
Breeding of TCR-transgenic Perfotin-defi~ent  Mice.  The  well-charac- 
terized line 318 (24, 25) oftransgenic mice expressing a T cell re- 
ceptor specific for the LCMV-GP nonapetide GP33 (amino acids 
33-41) in the context of the D b molecule was bred with perforin- 
deficient mice. The resulting ofs  were screened by cytoflu- 
orometry for  expression of the  transgenic v~2  segment.  Tram- 
genic mice, which were heterozygous at the perforin locus, were 
then  bred  inter  se  to  generate  homozygous  perforin-deficient 
TCP,  transgenic mice.  The  perforin genotype was  determined 
with PCP- and two different primer pairs on DNA prepared from 
tail biopsies. The first pair (5'-TTT TTG AGA CCC TGT AGA 
CCC A-3', 5'-GCA TCG CCT TCT  ATC GCC TTC T-3') 
yields a band of 665  bp for the mutated and is negative for the 
wild-type allele.  The  second  pair  (5'-CCG  GTC  CTG  AAC 
TCC  TGG CCA A-3', 5'-CCC  CTG CAC ACA TTA CTG 
GAA G-3')  yields a  300-bp  fragment for  the  wild-type and  a 
1,300-bp fragment for the mutated allele. 
Breeding of LCMV-GP  Transgenic Petforin-Deficient Mice.  Mice 
expressing a LCMV-GP transgene under the control of the rat in- 
sulin  promoter  have  been  previously described  (22,  23).  The 
C57BL/6 line Bln of these transgenic mice was crossed with per- 
forin-deficient mice  and  the  offsprings were  subsequently bred 
inter  se.  Screening  for  the  perforin  locus  was  as  above.  The 
LCMV-GP transgene was detected by PCP,  (primers: 5'-CAA 
GCA AGA TGT AGA GTC  TGC  C-3', 5'-GGC TTT  GGA 
CAT GAA CCG CCC-3') resulting in a 450-bp fragment. 
Cytofluorometry.  v#6 expressing T  cells were measured in blood 
by incubating blood cells at 4~  in BSS containing 2% FCS and 
0.2% NaN  3 with rat anti-mouse v~36 monoclonal antibody 44-22-1 
followed by FITC-conjugated goat anti-rat IgG (Southern Bio- 
technology, Birmingham AL). After washing and saturation of re- 
sidual second stage reagent with rat serum, the cells were stained 
with PE-conjugated CD4-specific antibody (Becton Dickinson, 
Mountain View, CA). Erythrocytes were lysed with FACS  |  lysis 
solution (Becton Dickinson) and the cell suspensions were ana- 
lyzed on a FACScan  |  flow cytometer (Becton Dickinson) using 
logarithmic scales. Viable lymphocytes were gated for by a com- 
bination of forward light scatter and 90  ~ side scatter. T  cells ex- 
pressing v136 are shown as histograms gated on CD4 § T cells. 
To  detect transgenic TCR  expression, peripheral blood cells 
were stained with PE-conjugated v~2-specific mAb B20.1  (Phar- 
Mingen, San Diego, CA)  (26)  and FITC-conjugated CD8-spe- 
cific antibody (Becton Dickinson). After lysis oferythrocytes with 
FACS lysis solution (Becton Dickinson) and washing, cell suspen- 
sions  were  analyzed  on  a  FACScan  flow  cytometer  (Becton 
Dickinson) using logarithmic scales. Viable cells were gated for by 
a combination of forward light scatter and 90  ~ side scatter. 
Cytotoxicity Assay.  RMA and MC57G target cells (both H-2  b) 
were  grown in vitro by standard cell culture techniques.  They 
were labeled either with or without 10  i0 M LCMV-GP-derived 
epitope peptide GP33  (aminoacids 33-41, KAVYNFATM (27)) 
with Na251CrO4 (Amersham Int., Bucks., UK) on a rocking plat- 
form for 2 h  at 37~  Target cells were washed and used at 104 
cells per well in round-bottomed 96-well plates mixed at various 
ratios with spleen effector lymphocytes in a final volume of 200 
p~l. The effector and target cells were pelleted by centrifugation 
and incubated for 5 h at 37~  in the presence of 5% CO2. Total 
release was  determined by  incubating target  cells with  0.5  M 
HC1.  70 ml supematant was removed and counted in an auto- 
mated  counting  station  (Cobra;  Canberra-Packard,  Meriden, 
CT), which calculated percent specific release as (sample release  - 
spontaneous release)  /  (total release-spontaneous release)  ￿  100. 
Viruses.  LCMV-WE was originally obtained from Dr. F. Leh- 
mann-Grube  (Hamburg,  Germany)  and  propagated  on  L929 
cells.  Recombinant vaccinia virus expressing the  full length  of 
LCMV glycoprotein precursor molecule (vacc-LCMV-GP) was a 
gift from Dr. D.H.L. Bishop (Institute of Virology, Oxford Uni- 
versity, Oxford UK) (28, 29).  Recombinant vaccinia virus stocks 
were grown on BSC 40 cells. The cells and culture supernatants 
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freezing and thawing, sonicated on ice for 30 s and centrifuged. 
Measurement of  Blood Glucose.  The glucose concentration in blood 
obtained from a tail vein was measured using Haemo-Glucotest 
strips (B6hringer, Mannheim, Germany). 
Immunohistochemistry.  Pancreata  were immersed  in Hank's bal- 
anced salt solution and snap frozen in liquid nitrogen. Cryostat sec- 
tions (5 ~m) of tissue were cut and fixed in cold acetone.  Sections 
were  incubated  with  rat  anti-mouse  monoclonal  antibodies 
YTS191.1  (anti CD4), YTS169.4.2  (anti-CD8)  (30) or F4/80 (anti- 
macrophage) (31), respectively.  Alkaline phosphatase-labeled  goat 
anti-rat antibodies,  followed by alkaline phosphatase-labeled  don- 
key anti-goat antibodies  (Tago, Burlingame,  CA) were used  as 
secondary reagents.  The substrate  for the red color reaction was 
naphtol AS-BI phosphate/New Fuchsin.  Insulin was detected on 
paraffin-embedded formalin fixed tissues with the insulin-specific 
monoclonal antibody AE9D6 (BioGenex Laboratories, San Ramon, 
CA).  Primary  antibodies  were  detected  by an  indirect  immu- 
noenzymatic staining  procedure with biotinylated anti-immuno- 
globulin antibodies  and a biotin/streptavidin-amplified horserad- 
ish  peroxidase  detection  system  (BioGenex  Laboratories).  The 
brown color reaction was developed with diarninobenzidin. 
Adoptive Transfer.  Pefforin-competent  or  perforin-deficient 
mice, both transgenic  for a LCMV-GP-specific TCR, were i.v. 
infected  with  2  ￿  106  PFU  vacc-LCMV-GP to  activate  the 
LCMV-GP-reactive transgenic T  cells. After 6 d,  5  ￿  106 spleen 
cells were adoptively transferred  into perforin-deficient mice ex- 
pressing  LCMV-GP  in  the  pancreas.  To  keep  the  adoptively 
transferred  T cells in an activated state, the recipients  were i.v. in- 
fected with 2  ￿  106 pfu vacc-LCMV-GP. Diabetes  was checked 
by measuring blood glucose levels. 
Results 
Negative Selection and Deletion of TCR-v[36  + T  Cells Is Not 
Influenced by the Absence of Petforin.  Autoimmune  diseases 
including diabetes type 1 may ensue due to failure of toler- 
ance establishment to self antigens, which subsequently be- 
come the target of an inflammatory disease process. To as- 
sess whether the lack ofperforin affects tolerance induction 
by  deletion  of autoreactive  cells  (32),  perforin-deficient 
Mls-1 a mice were generated by crossing with mice of the 
Mls-la-expressing  DBA/2  strain.  The  resulting  F1  mice 
were  then  bred  inter  se  to  achieve  homozygosity for the 
disrupted perforin allele. The presence ofMls-1 a was tested 
by a PCP, reaction detecting the endogenous provirus form 
of the  mouse  mammary tumour  virus MMTV(SW)  (33). 
Cytofluorometric  analysis  of spleen  cells  from  perforin- 
expressing  Mls-1 b,  perforin-expressing  Mls-P,  perforin- 
deficient Mls-1 b and perforin-deficient Mls-1 a mice showed 
that  Mls-la-specific  vp6 +  T  cells  were  absent  in perforin- 
deficient  as  well  as  in  perforin-expressing  Mls-1 a  mice. 
Thus,  negative  selection  is  independent  of the  cytotoxic 
protein  perforin  and  occurs normally in perforin-deficient 
mice. 
LCMV-GP-specific  Cytotoxic T Cell Responses Of  LCMVoGP 
TransgenicMice.  LCMV-GP  transgenic  mice  have  been 
studied  previously  (22).  It has been found that potentially 
autoreactive  LCMV-GP-reactive  cells  in  these  mice  are 
present  without  undergoing  negative  selection  or anergy. 
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Figure 1.  Deletion  of Mls-P  reactive TCR.-vt,6 expressing T cells in 
the absence of perforin. Vp6 expression in peripheral blood is shown as 
histograms ofCD4  + T cells. Mls-1  b perforin-expressing C57BL/6, Mls-P 
perforin-expressing DBA/2,  Mls-1  b perforin-deficient mice (C57BL/6 
genetic background) and Mls-P  perforin-deficient mice were tested by 
cytofluorometry for the presence of Mls-1  a reactive TCR-v136-expressing 
T cells. The latter mouse strain was generated by outcrossing perforin- 
deficient C57BL/6 mice to the Mls-P-expressing strain DBA/2. 
Instead, these T  cells ignore antigen expressed in the islets 
of the pancreas  and remain  quiescent unless  they are acti- 
vated by an infection with LCMV. This leads to a prolifer- 
ative  and  cytotoxic  LCMV-GP-specific  T  cell  response 
comparable  to  nontransgenic  mice.  The  T  cell  response 
also induces infiltration  of LCMV-GP-specific T  cells  into 
the  pancreas  and  diabetes.  Thus,  a prerequisite  to  test  the 
role ofperforin-dependent cytotoxicity with perforin-defi- 
cient  LCMV-GP  transgenic  mice  is  that  activation  of 
LCMV-GP-specific  T  cells  is  not  impaired  by partial  or 
complete  tolerance  mechanisms.  To  formally  prove  this 
point,  C57BL/6  normal  control  mice,  perforin-deficient 
nontransgenic  and  perforin-deficient  LCMV-GP  trans- 
genic mice were infected with  200  PFU LCMV-WE i.v. 
On day 8 after infection, spleen cells were tested for cyto- 
toxic activity on various target cells.  We have shown previ- 
ously  (16,  34,  35)  that  MC57G  cells  due  to  their  lack of 
Fas-expression  are  susceptible  only to  perforin-dependent 
cytotoxicity, whereas  Fas-expressing RMA  target  cells  are 
susceptible  to  perforin-  and  Fas-dependent  cytotoxicity. 
Thus,  cytotoxic activity of perforin-deficient  effector cells 
from  LCMV-GP  transgenic  and  nontransgenic  mice  on 
MC57G  target  cells  labeled  with  the  LCMV-GP  epitope 
nonapeptide  GP33  (LCMV-GP  aminoacids  33-41)  (27) 
was  completely absent  (Fig.  2).  On RMA  cells  incubated 
with  GP33  peptide,  in  contrast,  the  cytotoxic  activity  of 
perforin-deficient  effector cells,  which is  mediated  by the 
interaction  of Fas-ligand  on the T  cell with  Fas  expressed 
on the surface of the target cell (19, 34, 36-38), was mark- 
edly reduced compared to the activity ofC57BL/6 effector 
cells  but  clearly  detectable.  Spleen  cells  from LCMV-GP 
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Figure 2.  Ability  of LCMV-GP transgenic perforin-deficient mice to 
generate a LCMV-GP specific Fas-dependent cytotoxic T cell response. 
Normal  control  C57BL/6  mice (B6), pefforin-deficient (PKO), and 
LCMV-GP transgenic perforin-deficient (PKO-GP) mice were infected 
with 200 PFU LCMV-WE. After 8 d, the cytotoxic activity of spleen 
cells was tested on Fas-negative MC57G cells and Fas-expressing tt.MA 
cells. The target cells were either labeled with a main epitope peptide of 
LCMV-GP (GP33) or used without peptide to demonstrate specificity. 
The experiment was repeated twice with similar result. 
transgenic  and  nontransgenic  perforin-deficient  mice  spe- 
cifically lysed labeled RMA cells with similar efficiency in- 
dicating that the LCMV-GP transgene did not induce neg- 
ative  selection  or  anergy  of potentially  autoreactive  cells 
and  that  LCMV-GP-reactive  T  cells  are  present  in  the 
same numbers in transgenic and nontransgenic perforin-defi- 
cient mice. 
Diabetes Induction by LCMV Infection in Pe~orin-expressing 
but  Not  in  Perforin-defident  LCMV-GP  Transgenic Mice. 
Perforin-deficient  LCMV-GP  transgenic  mice  are  healthy 
and do not develop spontaneous insulitis.  As previously re- 
ported  (22),  perforin-competent  LCMV-GP  transgenic 
mice develop  insulitis  and diabetes  between  day 9  and  11 
after LCMV infection. To test the role of perforin-depen- 
dent  cytotoxicity in  the  induction  of diabetes,  pefforin- 
competent  and  perforin-deficient  LCMV-GP  transgenic 
mice were  infected  with  200  PFU  LCMV-WE  i.v..  The 
onset of diabetes was determined by measuring the level of 
blood glucose in regular intervals.  In contrast to perforin- 
competent  mice,  perforin-deficient  LCMV-GP  transgenic 
mice  did  not develop  diabetes  (Fig.  3).  Perforin-deficient 
mice do, however, develop weight loss of up to 20% after 
infection  and  eventually  die  between  day  15  and  25  as 
described earlier (16). However, this pathology was signifi- 
candy slower  than  the  induction  of diabetes  in  pefforin- 
expressing mice allowing the  observation of perforin-defi- 
cient mice for several days beyond the onset of diabetes in 
LCMV-GP  transgenic  perforin-expressing  control  mice. 
We found that whereas all of the perforin-competent mice 
developed diabetes  on  day  10  after  LCMV  infection,  the 
pefforin-deficient  LCMV-GP  transgenic  mice  failed  to 
develop  hyperglycemia.  One  of  four  perforin-deficient 
LCMV-GP transgenic  mice survived infection even up to 
32 d without developing diabetes. 
Histological Analysis of lnsulitis in Petforin-Deficient  LCMV-GP 
Transgenic Mice.  Pancreas pathology was further characterized 
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Figure 3.  Failure of LCMV-GP transgenic pefforin-deficient mice to 
develop  diabetes upon  LCMV  infection.  Perforin-deficient  (PKO), 
LCMV-GP  transgenic  (RIP-GP)  and  perforin-deficient LCMV-GP 
transgenic (PKO-GP) mice were infected with 200 PFU LCMV i.v. Dia- 
betes was detected by monitoring blood glucose levels after infection. 
Pefforin-deficient LCMV-GP  transgenic as  well as  perforin-deficient 
nontransgenic mice suffered from marked weight loss upon LCMV infec- 
tion and died without developing  diabetes. 
by histological analysis  on day 9  (Fig.  4).  This  time  point, 
shortly before diabetes onset in perforin-competent LCMV- 
GP transgenic mice, was chosen because it should be most 
informative about the lymphocyte populations involved in 
the depletion  of pancreatic  13 cells.  Both, perforin-compe- 
tent  and perforin-deficient  LCMV-GP  mice were free  of 
insulitis  before  infection  (Fig.  4,  upper two  rows). Upon 
LCMV  infection,  marked  lymphocytic  infiltration  of the 
pancreas in perforin-expressing LCMV-GP transgenic mice 
developed and was accompanied by a loss of secretory cells 
rich in cytoplasm. As previously described (22), CD4 + T  cells 
tended  to  be  localized  more  on  the  periphery  of islets 
whereas  CD8 +  T  cells  infiltrated  the  entire  islets.  In per- 
forin-deficient LCMV-GP transgenic  mice,  CD8 +  T  cells 
infiltrating  into  the  entire  islets  were  detected,  but  their 
number was lower than in perforin-expressing LCMV-GP 
transgenic mice. Only few CD4 + T  cells were found in the 
pancreas of pefforin-deficient mice and in most islets  a con- 
siderable  number of secretory cells  rich in cytoplasm were 
present.  Few F4/80 positive macrophages were detected in 
islets  of normal control as well as ofperforin-deficient mice 
(data not shown). 
Adoptive  Transfer of Activated LCMV-GP-Specific  T  Cells. 
LCMV-GP  transgenic  perforin-deficient  mice  fail  to  de- 
velop  diabetes  upon  LCMV  infection.  This  may be  ex- 
plained by a crucial role ofpefforin-dependent cytotoxicity 
exerted by CD8 § T  cells in the destruction of]3 cells in this 
model of autoimmune  diabetes.  However,  since perforin- 
deficient mice are unable to control the growth of LCMV, 
which is eliminated  in wild-type  C57BL/6  mice by day 8 
2146  Perforin-dependent Cytotoxicity in Autoimmune Diabetes Figure 4.  Histological analysis of pancreatic islets from LCMV-GP transgenic (+/+)  pefforin-expressing and perforin-deficient mice. Pancreatic sec- 
tions from either uninfected or LCMV infected (day 9 after infection with 200 PFU LCMV-WE i.v.) were stained with standard HE stain or used for im- 
munohistochemistry  with CD4- or CD8-specific antibodies. The respective CD4- or CD8-expressing cells appear black.  ￿ 
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abundant  virus-infected  cells  in  perforin-deficient  mice 
could account for the failure of pefforin-deficient LCMV-GP 
transgenic mice to  develop diabetes.  In fact, the  reduced 
lymphocytic infiltration observed in these mice would sup- 
port this notion. 
To exclude this latter possibility we avoided LCMV in- 
fection  by  using  an  experimental  approach  in  which 
LCMV-GP-specific T  cells are activated by infection with 
a  LCMV-GP  recombinant  vaccinia  virus  strain  (vacc- 
LCMV-GP). The main advantage  of this experiment was that 
the virus load in normal control and perforin-deficient mice 
did not vary significantly because perforin-deficient mice 
have an intact ability to control a number of cytopathic vi- 
ruses  including  vaccinia virus  (39).  Splenic  T  cells  from 
vacc-GP  infected  mice  were  adoptively  transferred  to 
LCMV-GP  transgenic  perforin-deficient  recipients.  To 
achieve a higher frequency of LCMV-GP-reactive T  cells, 
LCMV-GP-specific  TCR  transgenic  perforin-expressing 
or perforin-deficient mice were used as donors. Whereas all 
of  the  recipients  that  had  received  perforin-expressing 
TCR transgenic spleen cells developed high glucose levels on 
day  8  atier infection,  recipients of pefforin-deficient TCR 
transgenic  cells remained normoglycemic during the whole 
observation period of 60 d  (Fig. 5 A). To exclude the pos- 
sibility  that  spleen  cells  from  perforin-deficient but  not 
from perforin-expressing TCR-transgenic donors were re- 
jected by the recipients due to some minor genetic differ- 
ences, some recipients were infected with LCMV on day 
15 after adoptive transfer. LCMV infection induces a much 
more  vigorous  proliferative  response  of LCMV  specific 
CD8 + T  cells than vacc-LCMV-GP and therefore allowed 
the  amplification of LCMV-specific transgenic  T  cells  to 
easily detectable levels. 9 d after LCMV infection, the fre- 
quency of transgenic T  cells was determined by cytofluo- 
rometry with a TCR-v,~2-specific antibody. The transgenic 
TCR-v,~  2 segment, which is present in nontransgenic mice 
in less than 5% of CD8 + T  cells, was expressed on 88% of 
CD8 +  peripheral blood T  cells  in  recipients of perforin- 
deficient vs. 44% in recipients ofperforin-competent TCR 
transgenic spleen cells indicated that the failure ofperforin- 
deficient  spleen  cells  to  induce  diabetes  upon  adoptive 
transfer was not due to rejection of transferred cells (Fig. 5 
B). The more pronounced expansion ofTCR-transgenic T 
cells in recipients ofperforin-deficient spleen cells is proba- 
bly  explained  by  the  failure  of these  animals  to  control 
LCMV infection, which in turn leads  to stronger stimula- 
tion ofLCMV-GP-specific T  cells. 
Insulitis and Diabetes after Adoptive  Transfer of TCR Trans- 
genic Cells.  Pancreatic sections of  recipient mice were stained 
with HE-, CD4-, or CD8-specific antibodies. Immunohis- 
tological analysis of pancreatic sections was performed 10 d 
following adoptive transfer shortly after the  recipients  of 
perforin-expressing control spleen cells turned diabetic. As 
expected from the  high  glucose levels, recipients of per- 
forin-competent spleen cells displayed extensive damage to 
the islets  (Fig.  6,  top).  In fact, intact islets  with secretory 
cells  rich in  cytoplasm were absent and  only few infiltra- 
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Figure  5.  Activated perforin-deficient T  ceils fail to  induce diabetes 
upon adoptive  transfer.  (A)  Perforin-competent  (TCR  tg)  or perforin- 
deficient (PKO-TCRtg) mice transgenic for a LCMV-GP-specific TCR 
were  infected i.v.  with  2  X  106  PFU  vacc-LCMV-GP  to  activate  the 
LCMV-GP  reactive transgenic T  cells.  After 6  d,  5  ￿  106 spleen cells 
were adoptively transferred into mice expressing LCMV-GP in the pan- 
creas. To keep the adoptively transferred T  cells in an activated state, the 
recipients were i.v. infected with 2  ￿  106 PFU vacc-LCMV-GP. Diabe- 
tes was monitored by measuring blood  glucose levels. The  experiment 
was repeated twice with similar result. (B) Presence of TCR transgenic T 
cells in peripheral blood of recipients that were prepared as above but in- 
fected on day 14 after adoptive transfer with 200 PFU LCMV-WE and 
killed on day 9 after LCMV infection for cytofluorometric analysis. TCR 
transgenic cells are  found in  the TCR-v~e+/CD8 +  compartment.  The 
percentage ofTCR-v,~Texpressing CD8 + cells is given in addition. 
tions consisting mainly ofCD8 + T  cells marked the sites of 
previous  islets.  In  recipients  of perforin-deficient spleen 
cells, in contrast, the islets had a hypertrophic aspect due to 
high numbers of mainly CD8 + , but also CD4 + infiltrating 
T  lymphocytes (Fig.  6, bottom). Despite this very marked 
insulitis,  secretory cells, mostly scattered in groups of 5-10 
cells surrounded by lymphocytic infiltrate,  were still present. 
These cells reacted with an insulin-specific antibody dem- 
onstrating that they retained their capacity to produce insu- 
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not cause detectable  destruction  of 13 cells. 
Discussion 
We  have  used  a  transgenic  mouse  model  for  autoim- 
mune  diabetes  to  evaluate  the  role  of contact-dependent 
cytotoxicity vs. other effector mechanisms in 13 cell destruc- 
tion and  development  of diabetes.  In conclusion,  our  data 
indicate  that  perforin-dependent  cytotoxicity  is  crucial  to 
cause diabetes by ehminating islet 13 cells. Apparently other 
mechanisms  such  as  13  cell  cytotoxic  cytokines  or  Fas- 
dependent  cytotoxicity  are  not  efficient  enough  to  fully 
compensate  for the  lack  of perforin-dependent  cytotoxic- 
ity.  The result of the  adoptive  transfer experiment  also in- 
dicates  that  perforin-dependent  cytotoxicity  is required  in 
the late effector phase of the disease process and not in the 
early induction  phase to start the inflammatory infiltration. 
It was shown that the lack of functional perforin did not 
affect negative selection of v~6 expressing autoreactive T  cells 
in  Mls-1 a perforin-deficient  mice.  Also,  perforin-deficient 
LCMV-GP  transgenic  mice  develop  a  similar  LCMV-GP 
specific T  cell response  as nontransgenic  perforin-deficient 
mice.  Thus,  together with the  earlier observation that per- 
forin-deficient  mice have  normal  numbers  of CD4,  CD8, 
and  NK  marker  positive  cells  (16),  this  indicated  that  the 
lack of functional perforin does not affect the development 
and the  clonal deletion  of T  cells.  This  excluded  any indi- 
rect  effect of the  gene  disruption  on  the  T  cell  repertoire 
and  allowed  the  study  of perforin-dependent  cytotoxicity 
at the level of effector mechanisms. 
We  used  two  different  protocols causing diabetes in the 
presence  of  perforin-expressing  T  cells.  First,  perforin- 
expressing  and  perforin-deficient  LCMV-GP  transgenic 
mice were infected with LCMV.  This protocol leads to di- 
abetes between  day  9  and  11  in perforin-competent  mice 
but  failed  to  induce  hyperglycemia  in  perforin-deficient 
mice. In the second system, splenic T  cells from either per- 
forin-expressing  or  perforin-deficient  mice  were  activated 
by  an  infection  with  vacc-LCMV-GP  and  subsequently 
adoptively transferred  to LCMV-GP  transgenic  recipients. 
Again,  the perforin-expressing  cells induced  readily diabe- 
tes whereas perforin-deficient spleen cells did not. 
In the first experiment involving LCMV infection much 
fewer CD4 +  and CD8 + T  cells infiltrated the islets ofper- 
forin-deficient  than  normal control mice.  This may be in- 
terpreted  as  evidence  indicating  that  perforin-dependent 
cytotoxicity mediated by CD8 + T  cells leads to 13 cell dam- 
age and release  of [~ cell-associated antigens,  which  in turn 
are  taken  up  by local  antigen  presenting  cells  and  activate 
CD4 +  T  cells causing an inflammatory reaction  eventually 
attracting  additional  cell  populations  (40).  However,  we 
think  that the failure  of LCMV infected  perforin-deficient 
transgenic mice to develop marked infiltrations is rather ex- 
plained by the failure  of perforin-deficient  mice to control 
the  growth  of LCMV  (16,  18).  This  results  in  the  persis- 
tence  of high  LCMV  titers  in  many tissues  after infection 
potentially diverting LCMV-specific  effector cells and pre- 
venting  them  from  infiltrating  the  LCMV-GP-expressing 
pancreatic islets. 
In fact, this view is also strongly supported by the histo- 
logical analysis of pancreatic sections following the adoptive 
transfer of activated LCMV-GP-specific  T  cells.  Here,  the 
antigenic  load  in  normal  control  and  perforin-deficient 
mice was similar due to the use of LCMV-GP recombinant 
vaccinia virus.  A  very marked infiltration  of the  islet  con- 
sisting mainly ofCD8 + but also CD4 + T  cells developed in 
recipients  of perforin-deficient  spleen  cells.  This  indicated 
that insulitis  does  not  depend  on the release of [3 cell pro- 
teins  by perforin-dependent  cytotoxicity.  Recently,  it was 
found  that  132-microglobulin-deficient  NOD  mice  fail  to 
develop  diabetes  and  insulitis  indicating  that  in  the  NOD 
model system, CD8 + T  cells are required  for the initiation 
of the  autoimmune  islet-reactive  process.  Together  with 
Figure 6.  Histological analysis  of pancreatic islets from LCMV-GP transgenic mice after adoptive transfer with perforin-competent (+/+) or perforin- 
deficient (0/0) LCMV-GP-specific T cells. Spleen cell from vacc-LCMV-GP infected TCR. transgenic mice were adoptively transferred into LCMV-GP 
transgenic recipients. Histological sections from recipients on 10 d after adoptive transfer were either stained with HE, CD4-, CD8-, or insuhn-specific 
antibodies as indicated. The immunohistochemical stainings are rendered in black. ￿  400. 
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perforin-dependent  cytotoxicity this  renders it very likely 
that CD8 + T  cells are involved in the initiation of diabetes 
by mechanisms other than perforin-dependent cytotoxicity 
such as secretion of cytokines  (as for example IFN-~/and 
TNF-[3). 
For the effector phase, however, our data clearly indicate 
that perforin-dependent cytotoxicity is necessary for [3 cell 
destruction and development of diabetes. The activities of 
other potential  molecular effector mechanisms  are  appar- 
ently not sufficient to cause diabetes. These are Fas-depen- 
dent cytotoxicity, which is induced by LCMV infection of 
perforin-deficient LCMV-GP transgenic mice (Fig.  2), but 
may not be effective due to a lack of Fas-expression of islet 
cells (41), secretion ofcytokines (14, 42), especially oflL-1, 
which has been found to be specifically toxic to [3 cells in 
vitro,  and cytotoxic effects of reactive oxygen derivatives. 
We can not rule out that such alternative mechanisms can 
cause a limited degree of damage to [3 cells. But our results 
show that they are not efficient enough to cause the loss of 
more than 90% of 13 cells which is necessary to result in di- 
abetes. This is also  supported by the histological aspect of 
recipient islets  after adoptive  transfer of perforin-deficient 
cells  that  showed a  dramatic infiltration  of CD8 +  T  cells 
into the islets  without noticeable damage to 13 cells  in the 
very  same  islet.  Furthermore,  TNF-receptor  I--deficient 
LCMV-GP transgenic mice are equally sensitive  to LCMV- 
induced  diabetes  as  TNF  receptor  I-expressing  control 
mice (Mckall-Faienza, K., and P.S.  Ohashi,  manuscript in 
preparation), confirming the minor role of secreted TNF in 
the elimination of islet [3 cells. 
The failure of non-perforin mechanisms to mediate tis- 
sue damage in diabetes is in accord with earlier findings in two 
model systems for virus induced immunopathological hep- 
atitis.  In LCMV-  (16)  as well as hepatitis B  virus-induced 
hepatitis  in  mice  (43)  inactivation  of perforin-dependent 
cytotoxicity abolished liver cell damage completely. Thus, 
analogous to the above findings for diabetes, viral hepatitis 
is mainly mediated by perforin-dependent cytotoxicity with- 
out measurable pathogenic contribution of the Fas-depen- 
dent cytotoxicity pathway. This is remarkable, because hepa- 
tocytes express significant levels of Fas  and  are  extremely 
sensitive to injected Fas-specific monoclonal antibodies (44). 
Independent earlier evidence pointed to the importance of 
cytotoxicity in the development of  diabetes in the LCMV-GP 
model. It was found that diabetes develops on day 9-11 af- 
ter LCMV infection, shortly after the LCMV-specific cyto- 
toxic activity peaks on day 8. In addition, the disease devel- 
ops  in  CD4 +  T  cell- but  not  in  CD8 §  T  cell--depleted 
mice  (45),  consistent  with  a  crucial  role  of the  cytotoxic 
and a non-essential role of the helper T  cell subset. In the 
NOD model system, it has been shown that after adoptive 
transfer of spleen cells  from diabetic to young nondiabetic 
NOD mice, perforin-expression in CD8 + T  cells peaks on 
day 12 preceding hyperglycemia by 1-2 d (46). 
Which  cells  are  responsible for the  islet  destruction  by 
perforin-dependent  cytotoxicity? Both  CD8 +  T  cells  and 
NK cells are capable of mediating perforin-dependent cy- 
totoxicity  (16,  20),  whereas  CD4 +  T  cells  seem to  exert 
cytotoxicity in vitro predominantly via the  Fas-dependent 
pathway (47).  The following evidence favors the CD8 § T 
cells  as being responsible for destruction of 13 cells by per- 
forin-dependent  cytotoxicity.  First,  in  the  LCMV-GP 
transgenic model, diabetes fails to develop after in vivo de- 
pletion of CD8 + T  cells  (45).  Second,  only very few NK 
cells are found in the islet infiltrates in islets  from diabetic 
NOD mice (1, 46) and from a freshly diabetic human (48). 
And finally,  CD8 + but not CD4 + T  cells,  were found to 
express perforin in the islets of young diabetic NOD recip- 
ients  after  adoptive  transfer  of spleen  cells  from  diabetic 
NOD mice (46). 
These  conclusions  are  somewhat  contradictory  to  the 
findings that a CD4 + T  cell clone isolated from a diabetic 
NOD  mouse induces  diabetes in nondiabetic  NOD  mice 
(8)  and that CD4 + spleens cells from diabetic NOD  mice 
transfer diabetes to NOD-scid mice (49).  Immunohistologi- 
cal analysis  of islets  from diabetic NOD mice have shown 
that 60-70% of the infiltrating T  cells were CD4 + and only 
30-40% CD8 +.  In human diabetes, in contrast, two inde- 
pendent reports have shown that the infiltrate is dominated 
by CD8 + T  cells with only very few CD4 + T  cells present. 
These  analyses were performed by a  first group  with  the 
pancreas ofa 12-yr-old girl that died from ketoacidotic coma 
after having symptoms of diabetes for only a  month  (48) 
and by a second group investigating disease recurrence  in 
three  diabetic patients,  who received pancreas grafts from 
their corresponding identical twins and in one patient whose 
graft was from a HLA identical sibling (50).  In all of these 
cases,  the islet infiltrating CD8 + T  cells  outnumbered the 
CD4 + T  cells by far. Similarly, the insulitis in LCMV-GP 
transgenic mice is dominated by CD8 § T  cells with ~70% 
CD8 §  vs 30%  CD4 +  T  cells.  Thus,  the  islet  infiltrate  of 
LCMV-GP  transgenic  mice  and  of the  described  human 
cases  have a similar prevalence of CD8 +  T  cells,  whereas 
the  infiltrate in  the islets  of diabetic  NOD  mice contains 
more  CD4 +  T  cells.  These  findings  raise  the  question 
whether CD4 + T  cells may play a more prominent role in 
the NOD system than in human diabetes. 
In conclusion,  we have shown here for a model system 
of autoimmune  diabetes  that  insulitis  is  not  dependent 
upon  tissue  damage  by  perforin-dependent  cytotoxicity, 
that perforin, which is expressed mainly by CD8 + T  cells 
in islet infiltrates, plays an important role in the destruction 
of islet [3 cells and that other mechanisms or soluble factors 
produced by T  cells  or macrophages fail to cause elimina- 
tion of 13 cells with similar efficiency. 
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